| Liver Cancer - Drug Pipeline Analysis and Market | | | | therefore they are expected to treat patients for |
| Forecasts to 2016 | | | | whom no treatment options currently exist. |
| Summary | | | | This report is built using data and information |
| The industry analysis specialist's new report, "Liver | | | | sourced from proprietary databases, primary and |
| Cancer - Drug Pipeline Analysis and Market | | | | secondary research and in house analysis by |
| Forecasts to 2016" is an essential source of | | | | GlobalData's team of industry experts. |
| information and analysis on the global liver cancer | | | | Scope |
| market. The report identifies the key trends | | | | The scope of the report includes: |
| shaping and driving the global liver cancer market. | | | | - Annualized global liver cancer market revenues |
| The report also provides insight on the prevalent | | | | data from 2001 to 2009, forecast forward for |
| competitive landscape and the emerging players | | | | seven years to 2016. |
| expected to bring significant shift in the market | | | | - Geographies covered in this report include the |
| positioning of the existing market leaders. Most | | | | US, the UK, Italy, Spain, Germany, France and |
| importantly, the report provides valuable insight on | | | | Japan. |
| the pipeline products within the global liver cancer | | | | - Pipeline analysis data providing a split across |
| sector. | | | | different phases, mechanisms of action being |
| Analyzed that the liver cancer market has high | | | | developed and emerging trends. The first-in-class |
| unmet needs in terms of both efficacy and | | | | molecules are primarily Tumor Necrosis Factor |
| safety. More than 90% of patients diagnosed with | | | | Alpha (TNF-alpha) inhibitors, selective estrogen |
| liver cancer are between 45 years and 85 years | | | | receptor modulators and light activated therapies. |
| of age. Nexavar is the only available Food and | | | | - Analysis of the current and future market |
| Drug Association (FDA) approved treatment for | | | | competition in the global liver cancer market. Key |
| advanced liver cancer patients. However, the | | | | future market players covered are Bristol-Myers |
| median survival time in patients treated with | | | | Squibb, Pfizer Inc., F.Hoffmann-La Roche, Bayer |
| Nexavar is only three months more than for | | | | Ag, Onyx Pharmaceuticals, Kowa Pharmaceuticals |
| patients treated with placebo. Moreover, Nexavar | | | | and Celsion Corporation. |
| has a low safety profile. About 39% and 6% of | | | | - Insightful review of the key industry drivers, |
| Nexavar-treated patients reported grade 3 and | | | | restraints and challenges. Each trend is |
| grade 4 adverse reactions respectively. | | | | independently researched to provide qualitative |
| Therefore, the unmet need in the liver cancer | | | | analysis of its implications. |
| market was valued at 56%. This is expected to | | | | - Key topics covered include a strategic |
| decrease significantly between 2009 and 2016 due | | | | competitor assessment, market characterization, |
| to the expected launch of many first-in-class and | | | | unmet needs and the implications for future |
| me-too drugs. The majority of the first-in-class | | | | market associated with the liver cancer market. |
| drugs are for the early stages of liver cancer and | | | | |